|
|||||
|
|
NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial |
|
| Authors: | Leanne Dumeny Orly Vardeny Frank Edelmann Burkert Pieske Julio D. Duarte Larisa H. Cavallari |
| Affiliation: | 1. Center for Pharmacogenomics and Precision Medicine and Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA Genetics and Genomics, Genetics Institute, University of Florida, Gainesville, Florida, USA;2. Center for Care Delivery and Outcomes Research, Minneapolis Veteran Affairs Health Care System, Minneapolis, Minnesota, USA;3. Department of Internal Medicine and Cardiology, Charité University Medicine, Campus Virchow Klinikum, Berlin, Germany German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany Berlin Institute of Health (BIH), Berlin, Germany;4. Department of Internal Medicine and Cardiology, Charité University Medicine, Campus Virchow Klinikum, Berlin, Germany German Center for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany Berlin Institute of Health (BIH), Berlin, Germany Department of Cardiology, German Heart Center Berlin, Berlin, Germany;5. Center for Pharmacogenomics and Precision Medicine and Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA |
| Abstract: | |
| Keywords: | aldosterone receptor antagonists diastolic heart failure pharmacogenetics spironolactone |